Resources from the same session
Rationale for, and an orientation to, immunotherapy
Presenter: Lana Kandalaft
Session: Update on novel therapies in ovarian cancer
Resources:
Slides
Webcast
Where do we stand with PARP inhibitors in ovarian cancer treatment in 2019?
Presenter: Jonathan Ledermann
Session: Update on novel therapies in ovarian cancer
Resources:
Slides
Webcast
Do we already have biomarkers that may predict response and/or resistance to PARP inhibitors?
Presenter: Charlie Gourley
Session: Update on novel therapies in ovarian cancer
Resources:
Slides
Webcast
Conclusions and perspectives
Presenter: Ana Oaknin
Session: Update on novel therapies in ovarian cancer
Resources:
Slides